Abstract 36: CGM-derived dynamic measures of glycemia in relation to hepatic steatosis in adults without diabetes

B Bahar Bakhshi (Boston University School of Medicine, Dorchester, Massachusetts, United States) N Naznin Sultana (Boston University, Boston, Massachusetts, United States) I Ioanna Yiannakou (Boston University, Boston, Massachusetts, United States) M Matthew Nayor H Honghuang Lin (Framingham Heart Study, National Heart, Lung, and Blood Institute, National Institutes of Health and Boston University, Framingham, MA, USA.) D Devin Steenkamp (Boston University Medical Center, Boston, Massachusetts, United States) M Michelle Long M Maura Walker (Boston University School of Medicine, Dorchester, Massachusetts, United States) N Nicole Spartano (Boston University School of Medicine, Dorchester, Massachusetts, United States)

Abstract

Background: Prediabetes and type 2 diabetes are associated with increased risk for hepatic steatosis. Yet, the associations between dynamic measures of glycemia and hepatic steatosis among individuals without diabetes remains understudied. Methods: We included 1571 participants from the Framingham Heart Study (FHS) Third Generation based cohorts without diabetes who underwent assessment for hepatic steatosis using vibration-controlled transient elastography (2016-2019), had ≥3 days of continuous glucose monitor data (Dexcom G6 Pro CGM, 2022-2025) and completed a mixed meal tolerance test (MMTT, 2022-2025). The MMTT involved drinking a standardized nutritional beverage (600 kcal; 75 g carbohydrate, 21 g fat, 29 g protein). Hepatic steatosis was determined using controlled attenuation parameter (CAP). We performed multivariable linear and logistic regression to investigate the associations of standardized CGM-derived measures, fasting glucose, HbA1c, and 2-h post-MMT glucose with CAP as a continuous outcome and hepatic steatosis as a dichotomous outcome (CAP≥274dB/m). We adjusted all models for age, sex, smoking status, cholesterol-lowering medication, body mass index (BMI), and fasting blood glucose (except for when fasting glucose was used as a predictor). We also examined stratifying by glycemic status (normoglycemia and prediabetes). Results: In 1571 FHS participants (56.5% female, 55.3% normoglycemia), average age was 59.8y and BMI 28.2kg/m 2 . Steatosis prevalence was 21.4% among those with normoglycemia and 43.8% among those with prediabetes. Higher CGM measures of glycemic burden (e.g., %time above range [TAR] 140mg/dL) and 2-h post-MMTT glucose were positively associated with CAP (per 1 SD increase; β: 2.6 and 6.1, respectively, all p-value <0.05). Similarly, higher CGM measures and 2-h post-MMTT glucose were also associated with higher odds of hepatic steatosis (TAR 140; OR:1.25 [95% CI: 1.09–1.43], 2-h post-MMTT glucose; OR:1.41 [95% CI:1.23–1.62]). These associations appeared to be stronger among individuals with prediabetes and remained significant even after adjusting for BMI and fasting blood glucose. Conclusion: Glycemic burden and variability were associated with hepatic steatosis. CGM and MMTT may offer incremental value in identifying early metabolic dysregulation, beyond traditional measures of glycemia, particularly in those with prediabetes.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue Suppl_1
Published March 24, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

B

Bahar Bakhshi

Boston University School of Medicine, Dorchester, Massachusetts, United States

N

Naznin Sultana

Boston University, Boston, Massachusetts, United States

I

Ioanna Yiannakou

Boston University, Boston, Massachusetts, United States

M

Matthew Nayor

H

Honghuang Lin

Framingham Heart Study, National Heart, Lung, and Blood Institute, National Institutes of Health and Boston University, Framingham, MA, USA.

D

Devin Steenkamp

Boston University Medical Center, Boston, Massachusetts, United States

M

Michelle Long

M

Maura Walker

Boston University School of Medicine, Dorchester, Massachusetts, United States

N

Nicole Spartano

Boston University School of Medicine, Dorchester, Massachusetts, United States